3D Signatures (TSX:DXD) appointed Sherif Louis, as the company’s chief executive officer.
Dr. Louis was an early key contributor to the development of the company’s 3-D telomere technology and TeloView software platform dating back almost 15 years. He formally joined 3DS in September, 2015, and most recently held the position of director of clinical operations.
In a statement, Dr. Louis said he is a true believer in the power of the TeloView software platform. “I know the science intimately and I look forward to refocusing the company on large commercial opportunities in collaboration with strategic partners,” he added.
Hugh Rogers, interim chairman, said 3DS would focus on opportunities that provide leverage through academic, clinical and industry partnerships. “We are confident that Dr. Louis is the right person to lead operations during this critical transition,” he added.
